SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences (SLS) is surging as investor anticipation builds over the REGAL Phase 3 trial, with the community actively speculating on a potential buyout and a major short squeeze driven by significant short interest and impending trial milestones. Bulls are pointing to the extended survival data in the clinical trial as evidence of success, while bears maintain concerns regarding trial design, statistical significance, and potential dilution risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing significant price volatility as the semiconductor sector grapples with broader tech market fluctuations and shifting investor sentiment toward AI hardware. The community is actively debating the stock's valuation, with many traders monitoring its ability to maintain key support levels amidst intense algorithmic trading activity and mixed macroeconomic signals.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant volatility and trading volume as community members debate whether the asset is primed for a major short squeeze or trapped in a cycle of pump-and-dump behavior. Many are actively tracking support levels and liquidity shifts, while others express caution due to historical price swings and recent exchange delisting concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust (QQQ) is seeing intense community debate as investors navigate a complex mix of geopolitical escalations in the Middle East, volatility in global semiconductor markets, and active speculation around potential weekend market manipulation. Traders are closely monitoring key support levels and sector rotation trends while expressing skepticism toward the sustainability of current AI-driven valuations.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending as investors focus on its critical role in providing on-site, behind-the-meter power solutions to solve the grid bottleneck caused by rapidly expanding AI data centers. Community discussion is split between excitement over the company's long-term utility in the AI infrastructure buildout and intense debate regarding its valuation, volatility, and technical price movements following index rebalancing.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is surging as the market reacts to a strong earnings report that highlights the company's first-ever quarterly profit, accelerated user growth, and successful expansion into new consumer spending categories. Community discussion is heavily focused on the stock's massive upside potential compared to its fintech peers, while traders closely monitor the interplay between short interest, institutional accumulation, and looming legal catalysts.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending following the FDA approval and launch of Lumvoa, the first treatment for thyroid eye disease with labeling for both active and chronic forms of the condition. Community members are actively discussing the company's competitive positioning against existing blockbusters and are expressing strong interest in the upcoming conference call for updates on launch metrics and pricing strategy.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is currently a focal point of intense market speculation as institutional investors and the trading community debate the sustainability of its explosive AI-driven margin expansion and long-term memory supply constraints. The stock remains volatile following news of Apples attempts to source chips from Chinese suppliers and widespread community discussion regarding the validity of aggressive price targets as traders weigh institutional rebalancing against Micron's strategic dominance in the HBM sector.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is facing significant downward pressure as investors react to leadership turnover, ongoing workforce reductions, and concerns over cash burn and dilution. Despite community debate about the company's potential in the autonomous vehicle space through its robotaxi partnerships, the stock remains under heavy scrutiny due to consistent production challenges and a persistent struggle to reach profitability.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing intense community focus as institutional investors rotate into the stock following a significant Russell 2000 rebalancing and ongoing AI infrastructure buildout. Market participants are actively discussing potential short squeezes and institutional accumulation while monitoring upcoming earnings and strategic partnership announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS When the idmc unblinded actual MOS data from this ongoing Phase 3 trial, All Pooled MOS not yet met &gt; 13.5 months* - it told everyone who understands AML $ABBV Gps is Golden.  
  
BAT MOS is just 8 months. It ain’t working, BAT FAILED 4 Aml trials.  
SLS Share Price Launched on that Unblinded Interim Data at 60 Events, mcap quintupled, funds invested up 600%, Cash 10Xd - the market spoke and is speaking.

BigSkyBigMoney

Tony M

5,500% ROI this quarter

Captain

Jason

Barry

Chessdoc

$SLS thank you for posting this. 

Please post this every few hours because we are being inundated with new shareholders/investors who don’t know any better and are being relentlessly inundated with lies about this vaccine (GPS)  from trolls funded by shorts who are about to face unlimited financial disaster because they are trapped and can’t get out.

Last week shorts are reported to have lost $252 million on this drug. If that 80th event press release drops as we gamma squeeze that could be more like $5 billion or more.

The fact that the BAT drugs failed as an AML remission maintenance therapy is absolutely dispositive in the Regal trial. 

It is fatal to the bear case that somehow, someway these toxic medications that are BAT are keeping these AML CR2 patients alive and in remission for years. They are not. They don’t work.  The studies prove that.  They do not prevent relapse which is why the referenced studies were ended early for futility.  To date only stem cell transplants can prevent relapse (and only for some).￼

This is the BAT arm. It doesn’t work.   

The reason why almost 40% of Regal patients are living now at least 27 months and in most cases more like three and four years is because they’re taking GPS.  

These were people who had a death sentence in 6 to 9 months on average on BAT and have been saved.  Now could I be wrong?  Of course.  But the bear case founded on super BAT responders is absurd.

This is why I’m up to 79,200 shares and I was not early to this party.  ￼

I only started buying SLS at five dollars because that’s when I became convinced that due to the passage of so much time, Regal failure to meet its primary endpoint of OS (HR must be &lt; 0.636) seemed impossible or nearly impossible.  

I have absolute Personal conviction that Regal will succeed.  That is my opinion-not a fact.  That opinion is driving my own investment. 

Of course everyone must do their own due diligence and this is not financial advice.  I could be dead wrong.  And biotech investing in a development stage biotech can result in loss of the entire investment if things go wrong.

StockTwits for iOS

10xorbust

StockTwits Web

Abbvie Inc

 When the idmc unblinded actual MOS data from this ongoing Phase 3 trial, All Pooled MOS not yet met > 13.5 months* - it told everyone who understands AML 

 Gps is Golden.  
  
BAT MOS is just 8 months. It ain’t working, BAT FAILED 4 Aml trials.  
SLS Share Price Launched on that Unblinded Interim Data at 60 Events, mcap quintupled, funds invested up 600%, Cash 10Xd - the market spoke and is speaking.